PATENT CLAIM ANALYSIS

Application Number: 15748284
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.

Claim (Index 146):
The immune checkpoint inhibitor of any one of  claims 113 - 145 , wherein disease is cancer and the cancer is melanoma, squamous cell carcinoma, basal cell carcinoma, breast cancer, head and neck carcinoma, thyroid carcinoma, soft tissue sarcoma, bone sarcoma, testicular cancer, prostatic cancer, ovarian cancer, bladder cancer, skin cancer, brain cancer, glioblastoma, medulloblastoma, ependymoma, angiosarcoma, hemangiosarcoma, mast cell tumor, primary hepatic cancer, small cell lung cancer, non-small-cell lung cancer, pancreatic cancer, gastrointestinal cancer, renal cell carcinoma, hematopoietic neoplasia, lymphoma, mesothelioma, glioblastoma, low-grade glioma, high-grade glioma, pediatric brain cancer, medulloblastoma, or a metastatic cancer thereof.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 86.0
- Lexical Diversity: 1.19048
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14021353', '15170284', '14158531', '16068816', '15024396']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7473440416064139
- 35 USC 102 Novelty (BERT): 0.5389806496361189
- Combined Prediction Score: 0.7265077024093844
- Mean Citation Score: 364.48628
- Max Citation Score: 390.14835
- Similarity Product: 252.2766235757232

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test